CD19/CD22 bispecific CAR-T / Gan & Lee Pharma - LARVOL DELTA

CD19/CD22 bispecific CAR-T cells are effective in CD19 loss B-cell tumor models (AACR 2025) - "The CD19/CD22 bispecific CAR-T cells effectively kill B-cell tumors with CD19 loss both in vitro and in vivo, which will have a superior therapeutic effect on patients with relapse due to loss of CD19 protein."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Leukemia • Oncology • CD22 • CD8